Mukouda K, Morikawa E, Hasegawa K, Noumi K, Ohmura T, Mishima Y, Kawamoto M, Inagaki A, Kamitsuna A, Yamakido M, Nishimoto Y, Koyama T, Katsuta S
Gan To Kagaku Ryoho. 1983 May;10(5):1293-8.
A total of 36 cases with small cell carcinoma of the lung were treated with Ifosfamide. Fourteen cases (38.9%) out of 36 cases showed good or marked clinical response, and 120 mg/kg of Ifosfamide was necessary as a minimum dose to obtain effective response. As side effects of Ifosfamide, gastrointestinal disturbance (66.7%), depilation (66.7%), leukopenia (38.9%) and hematuria (36.1%) were observed. Mean survival time (M.S.T.) was prolonged by using Ifosfamide, comparing with the groups treated by with other anticancer drugs. Ifosfamide, therefore, should be used for the treatment of small cell carcinoma of the lung.
共有36例肺小细胞癌患者接受了异环磷酰胺治疗。36例患者中有14例(38.9%)显示出良好或显著的临床反应,异环磷酰胺的最低有效剂量为120mg/kg。异环磷酰胺的副作用包括胃肠道紊乱(66.7%)、脱发(66.7%)、白细胞减少(38.9%)和血尿(36.1%)。与使用其他抗癌药物治疗的组相比,使用异环磷酰胺可延长平均生存时间(M.S.T.)。因此,异环磷酰胺应用于肺小细胞癌的治疗。